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Abstract
Background:  Mitochondrial DNA (mtDNA) mutations account for at least 5% of cases of
postlingual, nonsyndromic hearing impairment. Among them, mutation A1555G is frequently found
associated with aminoglycoside-induced and/or nonsyndromic hearing loss in families presenting
with extremely variable clinical phenotypes. Biochemical and genetic data have suggested that
nuclear background is the main factor involved in modulating the phenotypic expression of
mutation A1555G. However, although a major nuclear modifying locus was located on
chromosome 8p23.1 and regardless intensive screening of the region, the gene involved has not
been identified.
Methods: With the aim to gain insights into the factors that determine the phenotypic expression
of A1555G mutation, we have analysed in detail different genetic and genomic elements on 8p23.1
region (DEFA3  gene absence, CLDN23  gene and MRPS18CP2  pseudogene) in a group of 213
A1555G carriers.
Results: Family based association studies identified a positive association for a polymorphism on
MRPS18CP2 and an overrepresentation of DEFA3 gene absence in the deaf group of A1555G
carriers.
Conclusion: Although none of the factors analysed seem to have a major contribution to the
phenotype, our findings provide further evidences of the involvement of 8p23.1 region as a
modifying locus for A1555G 12S rRNA gene mutation.
Background
Mitochondrial DNA (mtDNA) mutations are an impor-
tant cause of human disease and have been associated
with many clinical abnormalities, including various forms
of both syndromic and nonsyndromic hearing loss [1]. It
has been reported that at least 5% of cases of postlingual,
nonsyndromic hearing impairment are attributable to
known mtDNA mutations, representing one of the most
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frequent causes of hearing impairment [2]. The most com-
monly reported nonsyndromic deafness-causing mtDNA
mutations are a C insertion or deletion at position 961 [3-
5], C1494T [6,7] and A1555G [8-12] in the 12S rRNA
gene, and mutations A7445G [13-15], 7472insC [16,17],
T7510C [18] and T7511C [4,19,20] in the tRNASer(UCN)
gene.
In particular, the A1555G mutation has been associated
with aminoglycoside-induced and/or nonsyndromic
hearing loss in various families of different ethnic back-
grounds [8-12]. Remarkably, in Spain A1555G accounts
for about 15% of all familial and sporadic cases of hearing
loss, irrespective of their mode of inheritance and age of
onset [21]. The phenotype associated to A1555G muta-
tion varies considerably among matrilineal relatives, rang-
ing from severe deafness, to moderate progressive hearing
loss or even completely normal hearing. Biochemical and
genetic data suggest that nuclear background may be the
main factor involved in modulating the phenotypic
expression of the mutation [22-24]. Extensive genome
wide search revealed that nuclear modifying factors are
likely to be numerous, but a region in chromosome
8p23.1 has been proposed as a putative localization for a
modifier locus [22,23,25-27]. However, the gene involved
has not been identified yet.
Chromosome band 8p23.1 is known to be a frequent site
of chromosomal rearrangements mediated by low copy
repeats (LCRs) or segmental duplications (SDs). It has
been described that as many as one in four individuals
from the general population carry a 4.7 Megabase (Mb)
inversion of the region [28-30]. A high density of genes
are present in the region, and copy number variability
(CNV) involving both α-defensin (DEFA1 and DEFA3)
and β-defensin (DEFB4, DEFB103 and DEFB104) genes
has been well detected and characterized [31-34].
The objective of the present work was to analyse in detail
the contribution of different 8p23.1 genetic elements to
the phenotypic variability observed in deaf patients with
mitochondrial 12S rRNA A1555G mutation. The analysis
has focused on three different genomic features: DEFA3
gene absence, claudin23 (CLDN23) mutational analysis
and the putative function of a ribosomal mitochondrial
protein pseudogene (MRPS18CP2). These genes were
selected after an exhaustive screening of the region look-
ing for candidates as genetic modifiers of A1555G associ-
ated phenotype. Defensins were chosen because of their
close proximity to the positive linkage region and
CLDN23 and MRPS18CP2 were selected on the basis of
their putative biological function.
Methods
Patients and samples
Familial cases of sensorineural hearing loss have been col-
lected from different Spanish clinical centres with the aim
to study the molecular basis of hearing loss associated to
mtDNA A1555G mutation. The analysis was performed
on 213 patients, from 55 pedigrees with A1555G muta-
tion and 336 Spanish controls. The Spanish control sam-
ples were unrelated blood donor controls, all of
Caucasian origin. Informed consent was obtained from all
participants prior to their participation in the study, in
accordance with the Institutional Review Board and Ethic
Committee.
Clinical information such as the severity and age of onset
of hearing impairment, the exposure to some kind of oto-
toxic substances, specifically aminoglycosides, and any
other medical diagnoses were evaluated from at least one
member of each pedigree.
Detection of A1555G mutation
The detection of the A1555G mutation was either by PCR
amplification of a 340-bp fragment (Forward 5'-GCT-
CAGCCTATATACCGCCATCTTCAGCAA-3' and Reverse
5'-TTTCCAGTACACTTACCATGTTACGACTTG-3'), fol-
lowed by the digestion with restriction endonuclease
HaeIII, or alternatively using Pyrosequencing™ technology
(PSQ96MA) (Biotage AB, Sweden). A specific SNP assay
was designed for Pyrosequencing (Forward 5'-CGACATT-
TAACTAAAACCCCTACGC-3', Reverse 5'-GTTGGGT-
GCTTTGTGTTAAGCT-3' and Sequencing 5'-
CACTTACCATGTTACGACT-3' primers) and sequence
identification was performed automatically by the SQA
software.
DEFA3 determination
A PCR amplification assay followed by restriction enzyme
digestion (PCR-RFLP) has been used to discriminate
DEFA1 and DEFA3 gene alleles differing by a single nucle-
otide. A fragment of 304 bp around C3400A PSV was PCR
amplified with fluorescently labelled primers (Forward 5'-
TGAGAGCAAAGGAGAATGAG-3', Reverse 5'-GCAGAAT-
GCCCAGAGTCTTC-3') and digested with HaeIII enzyme.
About 2 μl of digestion product were added to 10 μl HiDi
formamide containing ROX500 marker (Applied Biosys-
tems) and run on an ABI 3100 capillary system (Applied
Biosystems). Peaks were analysed using Genemapper soft-
ware (Applied Biosystems).
Mutational screening
The genetic screening of CLDN23 gene and MRPS18CP2
pseudogene was performed by direct sequencing. The
entire coding sequence of CLDN23 gene was PCR-ampli-
fied in two different fragments of 483 bp (Forward 5'-
CCAGGAGGGAACTAGCCTAA-3' and Reverse 5'-BMC Medical Genetics 2007, 8:81 http://www.biomedcentral.com/1471-2350/8/81
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AGCGAGGTGACCATGAGTG-3') and 679 bp (Forward
5'-GACGAGCCCAACTTCGTG-3' and Reverse 5'-AGGCA-
GATTTCCATCCACAC-3'). The MRPS18CP2 pseudogene
was PCR amplified in a single fragment spanning 543 bp
(Forward 5'-CTCTGTTTACAGAAGACCTGG-3', Reverse
5'-TTTTAATCTAAAATCCATGTAGCAAA-3'). The resulting
PCR products were sequenced using an ABI PRISM® 3730
xl DNA Analyzer and ABI PRISM® BigDye Terminator v3.1
Sequencing Kit (Applied Biosystems).
Analysis of MRPS18CP2 expression
Analysis of MRPS18CP2 expression was assessed by RT-
PCR. We used total RNA isolated from lymphoblastoid
cell lines of general population subjects as well as total
adult RNA from ovary, liver, spleen, lung, placenta, kid-
ney, thymus, heart, skeletal muscle, testes, colon (Strata-
gene) and brain (Ambion). We employed 1 μg of total
RNA for reverse transcription using SuperScript First
Strand Synthesis System (Invitrogen). Reverse transcribed
RNA was then PCR amplified using specific primers for
MRPS18CP2  (Forward 5'-TGTTACAACCTTTAGGGTC-
CTTG-3', Reverse 5'-AGAGGTTGTTCACAATATAAAC-3').
Statistical analysis
To compare the proportion of DEFA3 absence in the dif-
ferent groups, between groups chi-square test was per-
formed.
Family based association tests were performed using FBAT
package [35]. FBAT decomposes large pedigrees into indi-
vidual nuclear families which are treated as independent
in most of the calculations. The analysis was performed
with 111 nuclear families, which belong to 33 large pedi-
grees, from which we have detailed phenotypic informa-
tion and were suitable for being analysed with FBAT
package. Bonferroni correction was used to account for
multiple testing, correcting for the number of tests per-
formed by the FBAT software.
For all statistical analysis performed, subjects were classi-
fied as affected or unaffected according to the available
clinical data. The phenotype of subjects with reported
aminoglycoside exposure was considered unknown.
The DEFA3  absence analysis was performed independ-
ently from the CLDN23 and MRPS18CP2 tests, consider-
ing only two different possible genotypes: present (with at
least one copy of DEFA3  gene) or absent (without
DEFA3). Heterozygotes for DEFA3  absence were only
annotated in those cases were the genotype could be
inferred from the pedigree data.
Results
α-defensin cluster is located in the positive linkage region 
on chromosome 8p23.1
Bykhovskaya and colleagues identified chromosome
8p23.1 as a major modifying locus for hearing loss pheno-
type associated to A1555G mutation [26,27]. Neither a
gene nor a genetic factor involved has been found, regard-
less of intensive screening of the region.
Genomic organization of chromosome 8p23.1 is charac-
terized by the existence of blocks of segmental duplica-
tions flanking the region, which are known to mediate a
4.7 Mb inversion [28]. The microsatellite markers with
highest lodscores in the linkage analysis [26,27] are
located telomerically with respect to the inverted region
and within a cluster of α-defensin genes (Figure 1).
Schematic representation of the α-defensin gene cluster on human chromosome 8p23.1 Figure 1
Schematic representation of the α-defensin gene cluster on human chromosome 8p23.1. The marker with higher 
lodscore in the linkage analysis is localized as well as all the genes in the region and the segmental duplication (positions are 
based on hg17, May 2004 genome assembly).
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The α-defensin cluster consists of five α-defensin genes
(DEFA6,  DEFA4, DEFA1,  DEFA3  and  DEFA5), five α-
defensin pseudogenes (DEFA8P,  DEFA9P,  DEFA10P,
DEFA11P and DEFA7P) and one θ-defensin pseudogene
(DEFT1P) [36]. Three copies of a 19-kb repeat unit or copy
number variant (CNV) were identified within the α-
defensin cluster, which correspond to the DEFA1A3 CNV
(based on May 2004 genome assembly). Each of the 19-
kb repeats contained a copy of the DEFA1  or  DEFA3
genes, but DEFA3 gene is known to be completely absent
in a significant proportion of the population
[26,27,32,34]. The description of these genomic features
is relevant for the search of genetic modifying factors for
A1555G mutation. Both, the presence of the polymorphic
inversion and CNVs involving the α-defensin gene cluster
could influence the phenotypic manifestation of deafness
linked to A1555G mutation.
With the aim to investigate the role of DEFA3 absence in
the phenotypic manifestation of A1555G mutation, we
analysed the absence of DEFA3 gene in a group of 55 hear-
ing impaired families or sporadic subjects with A1555G
mutation (213 subjects; 135 deaf and 78 hearing) and
336 unrelated blood donor controls, all of Caucasian ori-
gin. Twenty-one of the families analysed were previously
included in the whole-genome linkage analysis per-
formed by Bykhovskaya and colleagues [26,27]. In this
study, the families with non-parametric lodscore (Gene-
Hunter) above 0.8 were considered linked to chromo-
some 8p23.1, and below 0 unlinked. Using these criteria,
seven of the families tested (55 subjects; 31 deaf and 24
hearing) were considered linked to 8p23.1 and 14 (48
subjects; 30 deaf and 18 hearing) considered unlinked.
The frequency of individuals lacking DEFA3 in a control
population was determined. A group of 336 subjects were
tested for the absence of DEFA3, and found 42 individuals
in whom DEFA3 gene was absent (12.5%). No differences
were found in the rate of DEFA3 absence between deaf
and hearing subjects in any of the situations considered:
whole set of families, index cases versus control popula-
tion individuals or subjects from families linked to
8p23.1 region versus controls (Table 1). The data were
also analysed using a family based association test[35]
under a recessive mode of inheritance, as DEFA3 complete
absence is the only situation which could be unambigu-
ously determined with our assay. In this case, an over-rep-
resentation of DEFA3 absence was found in the affected
group (Z = 2.36; p = 0.018) (Table 2). No distinction
between linked and unlinked families was possible in this
case, because of lack of statistical power to perform the
calculations, as FBAT is based on the analysis of large sam-
ple groups.
CLDN23 gene is not involved in the phenotypic 
manifestation of A1555G
Claudins are a multigene family consisting of more than
20 members. They function as cell adhesion molecules
working at tight junctions. An important function in the
inner ear has been postulated for several claudin genes
[37,38]. Taking into account the function of other claudin
family members and the fact that CLDN23 gene is located
nearby (1.8 Mb) the defined linkage region in chromo-
some 8p23.1, it was selected for mutational screening as a
modifier candidate gene for A1555G deafness phenotype.
Sequencing of the CLDN23  gene coding sequence and
flanking regions in A1555G pedigrees resulted in the iden-
tification of eight sequence variants or polymorphisms,
five of them already reported in public databases (Figure
2). Three of the changes resulted in an amino acid change,
but none of them was identified in homozygosity, neither
the variants were found to segregate with the phenotype
in the pedigrees where they were identified. In addition, a
deletion of 12 bp in the 5'UTR of the gene was identified
in heterozygosity in one deaf sample. However, the pedi-
gree was not informative enough to state whether it has a
role in the deafness phenotype.
Although none of the variants segregated with the deaf-
ness phenotype in the analysed families, to completely
rule out the involvement of CLDN23 gene as a modifying
factor for A1555G mutation, a family based association
test was performed (Table 3). The test could be only per-
formed for two of the variants, as the others were found in
a small number of samples. No significant association was
Table 1: DEFA3 gene absence in A1555G patients and control subjects.
SAMPLES Phenotype DEFA3 NO DEFA3 p-value*
A1555G carriers (n = 213) Deaf (n = 135) 115 (85%) 20 (15%) 0.678
Hearing (n = 78) 69 (88%) 9 (12%)
A1555G carriers (n = 213) Deaf & Hearing 184 (86%) 29 (14%) 0.283
A1555G index cases (n = 55) Deaf 45 (82%) 10 (18%) 0.697
A1555G linked samples (n = 55) Deaf & Hearing 52 (95%) 3 (5%) 0.171
Controls (n = 336) 294 (87.5%) 42 (12.5%)
* Between groups chi-square p-value resulting from the comparison of deaf vs hearing carriers or carriers vs. control population subjects.BMC Medical Genetics 2007, 8:81 http://www.biomedcentral.com/1471-2350/8/81
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found for any of the SNPs comparing the expected vs.
observed transmission of each possible genotype (Table
3).
MRPS18C pseudogene located on 8p23.1 is expressed in 
humans
Pseudogenes, in the case of protein-coding genes, are gene
copies that have lost the ability to code for a protein. A
processed pseudogene, i.e. made through mRNA retro-
transposition, derived from mitochondrial ribosomal
protein S18C gene (MRPS18C) was identified 2 Mb cen-
tromeric from D8S1819, the marker with a highest posi-
tive linkagee score on chromosome 8p23.1. The
MRPS18CP2 pseudogene on chromosome 8p23.1 spans
293 bp, corresponding to the whole coding region of
exons 1, 2, 5 and 6 of MRPS18C gene, but lacking all
introns and exons 3 and 4. MRPS18CP2  pseudogene
shares 96,9% homology with MRPS18C nucleotide cod-
ing sequence. There are 13 nucleotide alterations and a 6
bp deletion compared to MRPS18C gene (Figure 3).
Despite lacking the original promoter, a processed pseu-
dogene can occasionally be transcribed [39]. In the public
databases, neither mRNAs nor ESTs are annotated for
Genetic variants identified in CLDN23 gene (A) and MRPS18CP2 pseudogene (B) Figure 2
Genetic variants identified in CLDN23 gene (A) and MRPS18CP2 pseudogene (B). The rs entry for the previously 
described SNPs or the nucleotide positions for the new identified SNPs are given. Arrows represent the position of the prim-
ers used for the PCR amplification of the corresponding genomic fragments.
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Table 2: Family based association study of DEFA3 gene absence in A1555G families.
Marker Genotype Freq Fam# S E(S) Var(S) Z P
DEFA3 present 0.689 9 8.00 6.83 2.69 0.71 0.477
absent 0.311 9 11.00 6.67 3.36 2.36 0.018**
# Number of informative families; S, observed transmission of genotype to affected offspring;
E(S), expected transmission under Mendelian inheritance; Var(S), variance; P, two-tailed P value;
**Significant P value after Bonferroni correction (P < 0.025).BMC Medical Genetics 2007, 8:81 http://www.biomedcentral.com/1471-2350/8/81
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MRPS18CP2  pseudogene in chromosome 8p23.1. To
check whether MRPS18CP2 is transcribed, its expression
was assessed by RT-PCR experiments using total RNA
from different human tissues, human lymphoblastoid cell
lines and mouse brain. A transcript containing
MRPS18CP2 was found to be expressed in all tested tis-
sues, except for human kidney, human skeletal muscle
and mouse brain (Figure 3).
Based on the physical localization of MRPS18CP2, its
expression pattern and the function of its corresponding
coding gene, MRPS18CP2, was selected for a genetic
screening as a candidate to be involved in the phenotypic
manifestation of A1555G mutation. The mutational
screening of MRPS18CP2 pseudogene in A1555G pedi-
grees resulted in the identification of seven polymor-
phisms, three of them already reported in public
databases (Figure 2). None of the SNPs segregate with the
deafness phenotype in any of the A1555G pedigrees ana-
lysed. A family based association analysis was also per-
formed for the two informative SNPs identified (Table 3).
In the case of SNP rs4841072, an overtransmission of the
AA genotype (Z = 2.26; p = 0.02) was found associated to
the disease, although after Bonferroni correction statisti-
cal significance was no longer supported (Table 3).
Discussion
Large-scale chromosomal rearrangements, such as dupli-
cations, deletions and inversions, are now known to be
common in the human genome [40]. The substrates for
these common rearrangements are generally highly
homologous sequences, known as segmental duplications
or LCRs, which flank the rearranged genomic segment
[41]. To take into account genomic structural variation is
crucial in linkage studies of human diseases for different
reasons. First, when a fixed marker order is assumed for all
individuals in an inverted region, one tends to see spuri-
ous recombination events among inversion carriers and/
or to find genotyping contradictions, which may lead to
discard some observations. In addition, the polymorphic
genomic structure of the rearranged regions, which apart
from large-scale genomic rearrangements can include
sequences that vary in copy number, might complicate the
mapping of putative disease genes. Chromosome 8p23.1
is such a region where a common neutral inversion medi-
ated by clusters of olfactory-receptor genes, is present in a
variable proportion of subjects, depending on the popula-
tion [28-30]. The position of a major nuclear modifier
gene for the deafness phenotype linked to A1555G
mtDNA mutation has been localized to chromosome
8p23.1 [27], but the identification of this gene has
remained elusive. This lack of progress may be partially
explained because of 8p23.1 genomic organization.
In an attempt to further study the putative genetic modi-
fying factors for A1555G mutation, including those
derived from the presence of segmental duplications, we
have performed a detailed analysis of three 8p23.1 candi-
date genetic features: CLDN23 gene, MRPS18CP2 pseudo-
gene and DEFA3  gene absence. CLDN23  gene and
MRPS18CP2  pseudogene were selected based on their
putative biological role in the inner ear, whereas DEFA3
gene absence was tested due to its close location to the
marker with a higher lodscore.
Claudins are essential components of tight junctions [42]
and therefore, they play important roles in the physiolog-
ical function of the inner ear. Tight junctions are well
developed in the epithelial cell layers that delineate the
inner ear compartments containing perilymph and endol-
Table 3: Family based association study of CLDN23 and MRPS18CP2 in A1555G families.
Gene Marker Genotype Freq Fam# S E(S) Var(S) Z P
CLDN23 rs9644774 GG 0.38 5 4.00 4.98 1.32 -0.82 0.41
GA 0.38 10 7.00 7.40 2.93 -0.24 0.81
AA 0.24 8 7.00 5.65 2.21 0.91 0.36
rs11995449 GG 0.56 6 7.00 6.17 2.06 0.58 0.56
GA 0.36 7 5.00 6.83 2.44 -1.17 0.24
AA 0.08 2 NA
MRPS18CP2 rs4841072 AA 0.38 8 13.00 8.78 3.48 2.26 0.02*
AC 0.31 9 6.00 9.28 4.03 -1.63 0.10
CC 0.31 3 NA
rs17154962 CC 0.85 5 4.00 6.28 2.00 -1.60 0.10
CT 0.15 5 7.00 4.55 2.17 1.67 0.09
TT 0.00 2 NA
SNPs with less than 5 informative families were excluded from the analysis. NA; not applicable.
# Number of informative families; S, observed transmission of genotype to affected offspring;
E(S), expected transmission under Mendelian inheritance; Var(S), variance; P, two-tailed P value;
*Significant p value < 0.05.BMC Medical Genetics 2007, 8:81 http://www.biomedcentral.com/1471-2350/8/81
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ymph, to prevent intercellular leakage of solutes and ions
[43]. In fact, mutation of the Claudin-14  gene was
reported to cause human hereditary deafness [38] and
Claudin-11 null mice exhibit severe deafness associated
with low endocochlear potential [37]. In addition, at least
10 species of claudins are expressed in the inner ear [44].
Pseudogenes are non-functional sequences of genomic
DNA originally derived from functional genes [45]. The
human genome encodes at least 79 mitochondrial ribos-
omal proteins from which more than 100 pseudogenes
have been identified [46]. Located on chromosome
8p23.1, there is MRPS18CP2, a processed pseudogene of
mitochondrial ribosomal protein S18C (MRPS18C). Five
other pseudogenes derived from MRPS18C  gene are
located in the human genome on chromosomes 3q26.1,
8p21.3, 12p13.31, 15q11.2 and 22q13.31 respectively
[46]. Interestingly, the MRPS18C pseudogene on chromo-
some 15q11.2 is located only 1-Mb apart from a micros-
atellite marker, which gave a positive linkage score in the
analysis performed by Bykovskaya and colleagues [26]. It
has been postulated that pseudogenes may play regula-
tory roles for the genes from which they have been
derived, such as serving as a source of antisense RNA [45].
Taking all these evidences into account and regardless that
MRPS18CP2 sequence and expression analysis Figure 3
MRPS18CP2 sequence and expression analysis. (A) Alignment of MRPS18CP2 pseudogene with MRPS18C mRNA (Gen-
Bank accession number NM_016067). Asterisks indicate sequence changes between the gene mRNA and the chromosome 
8p23.1 pseudogene. (B) RT-PCR experiments showing expression of a transcript containing MRPS18CP2 pseudogene in differ-
ent tissues.BMC Medical Genetics 2007, 8:81 http://www.biomedcentral.com/1471-2350/8/81
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the functional role of pseudogenes is not clear,
MRPS18CP2 was considered a good candidate.
None of the identified SNPs in either CLDN23  or
MRPS18CP2  segregate with the phenotype in A1555G
families, but as modifying factors are likely to be multiple
[25,26], this observation did not provide enough evi-
dence to completely discard their contribution in the
A1555G deafness phenotype. Thus, a family-based associ-
ation test was used to analyse the genotype data from
CLDN23  gene and MRPS18CP2  pseudogene. Family-
based association designs are particularly attractive, since
they test for linkage as well as association, avoid spurious
associations caused by admixture of populations, and are
convenient for investigators interested in refining linkage
findings in family samples [35]. With this approach, a
weak positive association with a single SNP in
MRPS18CP2 pseudogene was found. Although most of
the analysed samples come from the same geographic
area, founder effects do not account for the association
found as it was previously reported [47,48].
These results, although have to be taken with caution, are
of great interest as they may suggest a possible role for
MRPS18CP2 pseudogene. Three sequence variants have
been found for MRPS18 protein of the small mitochon-
drial ribosome subunit. In analogy to bacterial ribosomes,
it is likely that each mitochondrial ribosome contains a
single copy of MRPS18. Therefore, the presence of three
different isoforms suggests that there is a heterogeneous
population of mitochondrial ribosomes, which may have
different decoding properties and may be subjected to a
precise regulation of its expression [47]. The existence of
MRPS18 pseudogenes could play a role in the regulation
of each isoform expression, for example by blocking the
expression of the corresponding gene. If this is demon-
strated, it could explain the tissue specificity of A1555G
homoplasmic mtDNA mutation, leading to a clinical phe-
notype confined in the cochlea. Thus, additional studies
involving typing of additional SNPs in gene-coding and
regulatory regions in additional A1555G families are
needed, especially in the case of pseudogenes, whose
putative biological function is still unclear.
CNVs have been proposed to have an important role in
the pathological variation in the human population [49].
The DEFA1A3 CNV is located within the region previously
described to contain a major modifying locus for muta-
tion A1555G [32,34]. On the premise that the presence of
a gene in multiple copies could have a dosage effect and
therefore, contribute to genetic basis of some complex dis-
orders, it is feasible that the copy number polymorphism
of α-defensin cluster could be involved in the pathogene-
sis associated to the A1555G mutation. An overrepresen-
tation of DEFA3 gene absence was found in deaf A1555G
carriers. Defensins are small cationic peptides that form
an important part of the innate immune system. It is dif-
ficult to establish a direct relationship between defensin
function and A1555G deaf phenotype. However, as the
distinction between DEFA1 and DEFA3 is based on the
typing of a single SNP (C3400A), the differences in the
rate of DEFA3 gene absence observed between deaf and
hearing carriers of A1555G mutation could be considered
as a positive association signal that confirms the localiza-
tion of a modifier factor.
Conclusion
Both positive results found in MRPS18CP2 pseudogene
and  DEFA3  gene absence within the deaf group of
A1555G carriers are weak associations, which do not dem-
onstrate a role in the phenotype linked to A1555G
mtDNA mutation. However, they provide further evi-
dences of the involvement of 8p23.1 region as a modify-
ing factor for A1555G mutation. Further analyses in
additional families, as well as functional studies, which
should shed light on the function of these genetic features,
are needed in order to confirm or discard the associations
found between 8p23.1 genes and A1555G hearing
impairment.
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